179 related articles for article (PubMed ID: 16777663)
21. Fatty acid and phospholipid selectivity of different phospholipase A2 enzymes studied by using a mammalian membrane as substrate.
Diez E; Chilton FH; Stroup G; Mayer RJ; Winkler JD; Fonteh AN
Biochem J; 1994 Aug; 301 ( Pt 3)(Pt 3):721-6. PubMed ID: 8053897
[TBL] [Abstract][Full Text] [Related]
22. The neuromessenger platelet-activating factor in plasticity and neurodegeneration.
Bazan NG
Prog Brain Res; 1998; 118():281-91. PubMed ID: 9932449
[TBL] [Abstract][Full Text] [Related]
23. Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study.
Stanley JA; Williamson PC; Drost DJ; Carr TJ; Rylett RJ; Morrison-Stewart S; Thompson RT
Schizophr Res; 1994 Oct; 13(3):209-15. PubMed ID: 7841133
[TBL] [Abstract][Full Text] [Related]
24. New perspectives on the clinical neurobiology of treatment response in schizophrenia.
Honer WG
Can J Psychiatry; 1994 Feb; 39(1):34-42. PubMed ID: 7910778
[TBL] [Abstract][Full Text] [Related]
25. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.
Lieberman JA; Bymaster FP; Meltzer HY; Deutch AY; Duncan GE; Marx CE; Aprille JR; Dwyer DS; Li XM; Mahadik SP; Duman RS; Porter JH; Modica-Napolitano JS; Newton SS; Csernansky JG
Pharmacol Rev; 2008 Sep; 60(3):358-403. PubMed ID: 18922967
[TBL] [Abstract][Full Text] [Related]
26. Prostaglandins and other lipid mediators in Alzheimer's disease.
Bazan NG; Colangelo V; Lukiw WJ
Prostaglandins Other Lipid Mediat; 2002 Aug; 68-69():197-210. PubMed ID: 12432919
[TBL] [Abstract][Full Text] [Related]
27. Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding.
Horrobin DF; Jenkins K; Bennett CN; Christie WW
Prostaglandins Leukot Essent Fatty Acids; 2002 Jan; 66(1):83-90. PubMed ID: 12051959
[TBL] [Abstract][Full Text] [Related]
28. Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2.
Ross BM; Hudson C; Erlich J; Warsh JJ; Kish SJ
Arch Gen Psychiatry; 1997 May; 54(5):487-94. PubMed ID: 9152103
[TBL] [Abstract][Full Text] [Related]
29. Advanced glycation end products stimulate an enhanced neutrophil respiratory burst mediated through the activation of cytosolic phospholipase A2 and generation of arachidonic Acid.
Wong RK; Pettit AI; Quinn PA; Jennings SC; Davies JE; Ng LL
Circulation; 2003 Oct; 108(15):1858-64. PubMed ID: 12963645
[TBL] [Abstract][Full Text] [Related]
30. Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis.
Veerman SR; Schulte PF; Begemann MJ; de Haan L
Pharmacopsychiatry; 2014 Nov; 47(7):231-8. PubMed ID: 25121994
[TBL] [Abstract][Full Text] [Related]
31. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.
Konradi C; Heckers S
Biol Psychiatry; 2001 Nov; 50(10):729-42. PubMed ID: 11720691
[TBL] [Abstract][Full Text] [Related]
32. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies.
Fusar-Poli P; Berger G
J Clin Psychopharmacol; 2012 Apr; 32(2):179-85. PubMed ID: 22367656
[TBL] [Abstract][Full Text] [Related]
33. Integrating the neurobiology of schizophrenia. Preface.
Abi-Dargham A; Guillin O
Int Rev Neurobiol; 2007; 78():xiii-xvi. PubMed ID: 17349855
[No Abstract] [Full Text] [Related]
34. Increased calcium-independent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia.
Smesny S; Kinder D; Willhardt I; Rosburg T; Lasch J; Berger G; Sauer H
Biol Psychiatry; 2005 Feb; 57(4):399-405. PubMed ID: 15705356
[TBL] [Abstract][Full Text] [Related]
35. Antipsychotic drug effects on left prefrontal phospholipid metabolism: a follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients.
Smesny S; Langbein K; Rzanny R; Gussew A; Burmeister HP; Reichenbach JR; Sauer H
Schizophr Res; 2012 Jul; 138(2-3):164-70. PubMed ID: 22516552
[TBL] [Abstract][Full Text] [Related]
36. Alterations of brain membranes in schizophrenia: impact of phospholipase A(2).
Schaeffer EL; Gattaz WF; Eckert GP
Curr Top Med Chem; 2012; 12(21):2314-23. PubMed ID: 23279172
[TBL] [Abstract][Full Text] [Related]
37. The activation of phospholipase A2 and release of arachidonic acid and other lipid mediators at the synapse: the role of platelet-activating factor.
Bazan NG; Zorumski CF; Clark GD
J Lipid Mediat; 1993; 6(1-3):421-7. PubMed ID: 8395252
[TBL] [Abstract][Full Text] [Related]
38. Schizophrenia as a membrane lipid disorder which is expressed throughout the body.
Horrobin DF
Prostaglandins Leukot Essent Fatty Acids; 1996 Aug; 55(1-2):3-7. PubMed ID: 8888116
[TBL] [Abstract][Full Text] [Related]
39. Phospholipase A₂ activity in first episode schizophrenia: associations with symptom severity and outcome at week 12.
Smesny S; Kunstmann C; Kunstmann S; Willhardt I; Lasch J; Yotter RA; Proffitt TM; Kerr M; Marculev C; Milleit B; Milleit C; Nenadic I; Amminger P; McGorry PD; Sauer H; Berger GE
World J Biol Psychiatry; 2011 Dec; 12(8):598-607. PubMed ID: 21143005
[TBL] [Abstract][Full Text] [Related]
40. Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity.
Fumagalli F; Molteni R; Roceri M; Bedogni F; Santero R; Fossati C; Gennarelli M; Racagni G; Riva MA
J Neurosci Res; 2003 Jun; 72(5):622-8. PubMed ID: 12749027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
